Prof. Zelig Eshhar, PhD

Prof. Zelig Eshhar, PhD
Double - CAR strategy for specific and safe targeting of CAR T cells to ovarian tumors. The major challenge of “off-tumor on-target” toxicity in CAR therapy is the risk of damage to healthy tissues which express the target antigen of the selected CAR. The idea underlying our approach is that this toxicity can be prevented by restricting the activity of CAR cells against combinations of two antigens which are co-expressed by the tumor, but not by normal tissues. In the first two years of the study, we aimed to develop a new CAR T cell therapy for multiple myeloma (MM). Our work began by confirming, in-vitro, the expression and functionality of the selected recognition and signaling moieties. Currentlythe research team is conducting in vivo experiments, analyzing this novel approach in mice bearing human multiple myeloma tumors. 

 

Contact info:
Prof. Zelig Eshhar PhD
Tel-Aviv Sourasky Medical Center
zelige@tlvmc.gov.il

https://www.tasmc.org.il/sites/en/Personnel/pages/eshhar-zelig.aspx

Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel
UI/UX Basch_Interactive